Neovascular AMD necessitates repeated intravitreal injections of anti-vascular endothelial growth factor (VEGF) drugs, whereas there is currently no clinical treatment available that can slow progression or restore vision in cases of geographic atrophy (24). The gene discussed is VEGFA; the disease is atrophic macular degeneration.